Citations

Mayo Clinic

Clear

13598 citation(s) found for "_, _".

Titin Isoforms, Extracellular Matrix, and Global Chamber Remodeling in Experimental Dilated Cardiomyopathy
Jaber, Wissam , Maniu, Calin V., Krysiak, Judith , Shapiro, Brian P. , Meyer, Donna , Linke, Wolfgang A. , Redfield, Margaret M. , Linke, Wolfgang A

Circulation: Heart Failure | June 26, 2008 | Volume: 1 | Issue: 3 | Pages: 192-199

10.1161/circheartfailure.108.768465 | PMID 19808289 Get It

Background— Altered titin isoforms may modify cardiac function in heart failure (HF), but the nature of isoform switches and associated functional implications are not well defined. Limited studies have reported an increased compliant isoform (N2BA) expression in human systolic HF. Titin may also modulate stretch-regulated responses such as myocardial natriuretic peptide production. Methods and Results— We characterized titin isoform expression and extracellular matrix in all 4 cardiac chambers and the left ventricular (LV) epicardium and endocardium in normal dogs (n=6) and those with HF (n=6) due to tachypacing and characterized functional implications at the LV myofiber and chamber level. Recognizing the potential for uncoupling of the extracellular matrix and cardiomyocyte in tachypacing, myocardial natriuretic peptide production, a molecular marker of stretch-regulated responses, was also assessed. All chambers were dilated in HF, but the extracellular matrix was not increased. HF dogs had markedly lower N2BA in the atria and right ventricle. In failing LVs, N2BA was decreased only in the epicardium, where myofiber passive stiffness was increased. However, LV chamber mechanics were driven by the marked LV dilatation, with no increase in LV diastolic stiffness. Natriuretic peptide concentrations increased markedly in the endocardium in relation to increases in LV wall stress. Conclusions— Tachypacing HF is characterized by decreases in compliant titin isoform expression in the atria, right ventricle, and LV epicardium. However, LV chamber mechanics are principally determined by geometric and extracellular matrix changes rather than titin-based myofiber stiffness in this model. Stretch-regulated myocardial responses (natriuretic peptide production) appeared intact, suggesting that the mechanotransduction role of titin was not impaired in HF.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Rassenti, Laura Z., Jain, Sonia , Keating, Michael J. , Wierda, William G. , Grever, Michael R. , Byrd, John C. , Brown, Jennifer R. , Greaves, Andrew, Rai, Kanti R., Byrd, John C. , Kay, Neil E. , Gribben, John G. , Neuberg, Donna , He, Feng , Rai, Kanti R., Kipps, Thomas J. , Byrd, John C

Blood | June 25, 2008 | Volume: 112 | Issue: 5 | Pages: 1923-1930

10.1182/blood-2007-05-092882 | PMID 18577710 Get It

AbstractLeukemia-cell expression of ZAP-70, CD38, or unmutated immunoglobulin heavy chain variable region genes (U-IGHV) each is associated with aggressive disease in patients with chronic lymphocytic leukemia (CLL). To assess the relative strength of each marker, we defined thresholds for designating a case as positive for CD38 or ZAP-70 in a test cohort of 307 patients and used these data-defined criteria to stratify patients in an independent cohort of 705 patients. Multivariable analysis revealed that ZAP-70 was the strongest risk factor. Knowledge of the IGHV mutation status or CD38 did not improve our ability to predict the time to first treatment except for ZAP-70–negative cases, which could be segregated into 2 groups of intermediate-risk or low-risk disease based on whether they expressed unmutated or mutated IGHV. ZAP-70 maintained its high relative prognostic value for the subset of patients with early-stage, asymptomatic disease, including patients evaluated within 1 year of diagnosis. Although it is premature to recommend therapy based on these risk factors, patients with ZAP-70–positive CLL cells should be monitored closely for disease progression as they have a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3 years.
Biologic and genetic characterization of the novel amyloidogenic lambda light chain–secreting human cell lines, ALMC-1 and ALMC-2
Arendt, Bonnie K., Ramı́rez-Alvarado, Marina , Sikkink, Laura A., Keats, Jonathan J. , Ahmann, Gregory , Dispenzieri, Angela , Fonseca, Rafaël , Ketterling, Rhett P. , Knudson, Ryan A., Mulvihill, Erin M., Tschumper, Renee C. , Wu, Xiaosheng , Zeldenrust, Steven R., Jelinek, Diane F., Dispenzieri, Angela , Ramirez-Alvarado, Marina , Ketterling, Rhett P , Keats, Jonathan J , Fonseca, Rafael

Blood | June 21, 2008 | Volume: 112 | Issue: 5 | Pages: 1931-1941

10.1182/blood-2008-03-143040 | PMID 18567838 Get It

AbstractPrimary systemic amyloidosis (AL) is a rare monoclonal plasma cell (PC) disorder characterized by the deposition of misfolded immunoglobulin (Ig) light chains (LC) in vital organs throughout the body. To our knowledge, no cell lines have ever been established from AL patients. Here we describe the establishment of the ALMC-1 and ALMC-2 cell lines from an AL patient. Both cell lines exhibit a PC phenotype and display cytokine-dependent growth. Using a comprehensive genetic approach, we established the genetic relationship between the cell lines and the primary patient cells, and we were also able to identify new genetic changes accompanying tumor progression that may explain the natural history of this patient's disease. Importantly, we demonstrate that free lambda LC secreted by both cell lines contained a beta structure and formed amyloid fibrils. Despite absolute Ig LC variable gene sequence identity, the proteins show differences in amyloid formation kinetics that are abolished by the presence of Na2SO4. The formation of amyloid fibrils from these naturally secreting human LC cell lines is unprecedented. Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology.
Progenitor Cell Therapy in a Porcine Acute Myocardial Infarction Model Induces Cardiac Hypertrophy, Mediated by Paracrine Secretion of Cardiotrophic Factors Including TGFβ1
Doyle, Brendan, Sorajja, Paul , Hynes, Brian, Kumar, Arun , Araoz, Phillip A., Stalboerger, Paul G., Miller, Dylan V. , Reed, Cynthia , Schmeckpeper, Jeffrey , Wang, Shaohua , Liu, Chunsheng , Krüger, David , Riederer, Stephen J. , Caplice, Noel M. , Sorajja, Paul , Terzic, André

Stem Cells and Development | June 18, 2008 | Volume: 17 | Issue: 5 | Pages: 941-952

10.1089/scd.2007.0214 | PMID 18564032 Get It

The Trigeminal Trophic Syndrome: An Unusual Cause of Face Pain, Dysaesthesias, Anaesthesia and Skin/Soft Tissue Lesions
Garza, Ivan

Cephalalgia | June 16, 2008 | Volume: 28 | Issue: 9 | Pages: 980-985

10.1111/j.1468-2982.2008.01636.x | PMID 18557978 Get It

The trigeminal trophic syndrome is an unusual consequence of trigeminal nerve injury that results in facial anaesthesia, dysaesthesia and skin ulceration. Limited knowledge is available. The aim of this study was to increase the knowledge of this syndrome by performing a retrospective medical record review and case series report. Fourteen cases were identified. The female : male ratio was 6:1. Mean age of onset was 45 years (range 6-82). The cause was iatrogenic in most. Latent period to onset ranged from days to almost one decade. The majority ( n = 12) had bothersome dysaesthesias. Most ( n = 9) self-manipulated the face; a third ( n = 5) did not. Most ulcers affected the second trigeminal division, mainly in the infraorbital nerve distribution. Neuropathic and/or neuralgic facial pain occurred in 50% ( n = 7). Pain intensity was severe in most (n = 6). Gabapentin gave relief in two. To conclude, trigeminal trophic syndrome follows injury to the trigeminal nerve or its nuclei. For unclear reasons, most ulcerations follow infraorbital nerve distribution. Self-manipulation may contribute to ulcer development rather than being required. Gabapentin may help pain.
Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Verstovšek, Srđan , Tefferi, Ayalew , Cortes, Jörge E. , O’Brien, Susan , Garcia‐Manero, Guillermo , Pardanani, Animesh , Akin, Cem , Faderl, Stefan, Manshouri, Taghi , Thomas, Deborah A. , Kantarjian, Hagop M. , Cortes, Jorge , Verstovsek, Srdan , Akin, Cem , Kantarjian, Hagop

Clinical Cancer Research | June 16, 2008 | Volume: 14 | Issue: 12 | Pages: 3906-3915

10.1158/1078-0432.ccr-08-0366 | PMID 18559612 Get It

Abstract Purpose: Molecular characterization of Philadelphia chromosome–negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor β TKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph− myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.
Familial and Perceived Risk of Breast Cancer in Relation to Use of Complementary Medicine
Myers, Cynthia D., Jacobsen, Paul B. , Frost, Marlene H., Cerhan, James R. , Sellers, Thomas A. , Huang, Yifan , Patten, Christi A. , Cerhan, James R

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2008 | Volume: 17 | Issue: 6 | Pages: 1527-1534

10.1158/1055-9965.epi-08-0028 | PMID 18541615 Get It

Abstract Aim: To examine the use of complementary and alternative medicine (CAM) by women with varying levels of familial and perceived risk of breast cancer with the goal of preventing breast cancer. Methods: Cross-sectional data on CAM use were collected on 2,198 women (mean age, 63 years) personally unaffected by breast cancer in the Minnesota Breast Cancer Family Study. CAM use was compared across women at high, moderate, or average risk based on family history, as well as across categories of perceived risk of breast cancer. CAM use was also examined in relation to screening and general health behaviors, worry about breast cancer, and optimism. Results: Half (49.5%) of the women reported using at least one CAM modality with the intent of preventing breast cancer. Univariate analyses indicated that greater overall CAM use was related to greater perceived risk (P = 0.018), more general health behaviors (P < 0.0001), more breast cancer screening behaviors (P = 0.0002), greater optimism (P = 0.0002), and higher educational attainment (P < 0.0001). Multivariate analysis revealed that general health behaviors (P < 0.0001), education (P = 0.0027), and optimism (P = 0.037) were significant predictors of CAM use when in the same model with perceived risk and breast cancer screening behaviors. Conclusions: Many women use CAM with the goal of preventing breast cancer. General health-promoting behaviors, education, and optimism predict CAM use. Evidence-based guidance is needed for the public and health care providers on the potential and limitations of specific CAM approaches to affect cancer risk. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1527–34)
Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Funder, John W. , Carey, Robert M. , Fardella, Carlos , Gómez-Sánchez, Celso E. , Mantero, Franco , Montori, Víctor M. , Stowasser, Michael , Young, William F. , Montori, Victor M

The Journal of Clinical Endocrinology & Metabolism | June 13, 2008 | Volume: 93 | Issue: 9 | Pages: 3266-3281

10.1210/jc.2008-0104 | PMID 18552288 Get It

Polymorphisms in DNA Repair Genes, Smoking, and Pancreatic Adenocarcinoma Risk
Bamlet, William R. , Cunningham, Julie M. , Goode, Ellen L. , Boardman, Lisa A., Petersen, Gloria M. , McWilliams, Robert R. , Andrade, Mariza de , Boardman, Lisa A., Bamlet, William R

Cancer Research | June 11, 2008 | Volume: 68 | Issue: 12 | Pages: 4928-4935

10.1158/0008-5472.can-07-5539 | PMID 18544627 Get It

Abstract Base excision repair and nucleotide excision repair are vital responses to multiple types of DNA damage, including damage from tobacco exposure. Single-nucleotide polymorphisms (SNP) in these pathways may affect DNA repair capacity and therefore influence risk for cancer development. We performed a clinic-based, case-control study comprising 481 consecutive patients with confirmed pancreatic adenocarcinoma and 625 healthy controls. Allele and genotype frequencies for 16 SNPs in DNA repair genes ERCC1, XPD/ERCC2, XPC, XPF/ERCC4, OGG1, and XRCC1 were compared after adjusting for age, sex, and smoking history. Subgroup analysis by sex and smoking history was performed. Carriers of one or two XPF/ERCC4 minor alleles at R415Q had decreased risk of pancreatic adenocarcinoma compared with those who had two major alleles [odds ratio (OR), 0.59; 95% confidence interval (95% CI), 0.40–0.85]. Heavy smokers (>40 pack-years) had increased risk for cancer if they were carriers of at least one minor allele for XPD/ERCC2 at D312N (OR, 2.78; 95% CI, 1.28–6.04) or D711D (OR, 2.19; 95% CI, 1.01–4.73). No other significant differences in risk were identified. Minor alleles in DNA repair genes XPF/ERCC4 and XPD/ERCC2 were associated with altered risk for pancreatic cancer. [Cancer Res 2008;68(12):4928–35]
On the Calculation of Radiation Force on Spheres Due to Arbitrary Spatially Distributed Acoustic Beams
Silva, Glauber T. , Fatemi, Mostafa , Fatemi, Mostafa

Volume 1: 20th Biennial Conference on Mechanical Vibration and Noise, Parts A, B, and C | June 10, 2008 | Volume: No volume available | Issue: No issue available | Pages: 2621-2626

10.1115/detc2005-85660 Get It

This work presents a theory for the acoustic radiation force exerted on a solid sphere by an arbitrary spatially distributed beam. The theory is developed for an sphere suspended in an ideal fluid. We assume that the acoustic beam can be decomposed in a set of plane waves with same frequency, propagating in different directions. The sphere radius is considered to be much smaller than the wavelength of the beam. Bulk properties of the sphere such as shear and compressional sound speed are taken into account. The radiation force is obtained by solving the linear acoustic scattering problem for the sphere. Theoretically, the radiation force depends on the sphere cross section area, the radiation force function, and the vector energy flux upon the sphere. The radiation force function is related to the sphere scattering properties. We apply the developed theory to study the radiation force produced by an spherical concave transducer. The generated radiation force can be decomposed into two components, namely, axial and transverse with respect to the wave propagation direction. The ratio between the transverse and axial components of the force depends on the transducer F-number and wave frequency. Results show that this ratio for a 2 MHz transducer with 3.5 F-number on the focal plane is less than 5%.